Project Grant R35HL177135
Award Date
4/1/25
Completion Date
3/31/32
Dollars Obligated
$1.1M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This $503,496 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to improve treatment and outcomes for patients with hospital-onset sepsis at risk of acute respiratory failure (ARF). The key objectives are to: 1) Identify different clinical presentation phenotypes of hospital-onset sepsis, 2) Develop a predictive model to forecast ARF risk in these patients, and 3) Assess how...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $200,502 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to The Regents of the University of California, San Francisco (UCSF) to support research on proteomic and metabolomic trajectories of acute respiratory distress syndrome (ARDS) molecular phenotypes. The funding will allow the principal investigator, Dr. Narges Alipanah-Lechner, to develop expertise in computational methods, epidemiologic approaches, and systems...
This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop and validate an electronic health record (EHR)-embedded system to classify molecular phenotypes of acute respiratory distress syndrome (ARDS) and sepsis at the bedside. The primary objectives are to: 1) evaluate the longitudinal performance of a machine learning-based Clinical Classifier Model (CCM) in identifying...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is focused on investigating alveolar macrophage (AM) subset ontogeny and function in the context of acute respiratory distress syndrome (ARDS).
The primary objective is to determine how AM subset ontogeny and function contribute to ARDS clinical outcomes. The $730,876 award supports a 5-year project that includes mechanistic investigations...
This federal Project Grant award, valued at $704,795.00 and provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a cell-based therapy platform for the treatment of acute respiratory distress syndrome (ARDS).
The key products or services to be delivered under this grant include:
Engineering retinal pigment epithelial (RPE) cells to produce anti-inflammatory cytokines (IL-1RA and IL-10) and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $186,408 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Washington to conduct research on targeting cluster of differentiation 14 (CD14) as a potential therapeutic approach for acute respiratory distress syndrome (ARDS). The five-year grant, running from September 1, 2024 to August 31, 2029, aims to: 1) analyze the effects of the CD14-blocking monoclonal antibody IC14 on blood leukocyte gene...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $153,099 to the Massachusetts Institute of Technology (MIT) to conduct research on dynamic treatment regimes for acute respiratory distress syndrome (ARDS) patients. The key activities involve using target trial emulation and g-methods to analyze observational data from large critical care databases, in order to evaluate the...
This $827,682 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to characterize pulmonary perfusion and develop imaging approaches to guide treatment of Acute Respiratory Distress Syndrome (ARDS). The awardee, The General Hospital Corporation's Research Management Division (doing business as Massachusetts General Hospital), will leverage dynamic contrast-enhanced CT, dual energy CT,...
This $480,990 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) Cardiovascular Diseases Research program (CFDA 93.837) supports research on the role of aerocytes, a specialized capillary endothelial cell population, in alveolar epithelial regeneration following acute lung injury. The research aims to investigate how aerocyte-derived signaling, particularly the R-spondin3 molecule, guides the regenerative remodeling of alveolar epithelium and establishes a...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $782,362 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, Los Angeles (UCLA) to investigate the role of TREK-1 potassium channels in acute respiratory distress syndrome (ARDS). The project will utilize novel pharmacological and genetic tools, as well as advanced experimental ARDS models, to determine if TREK-1 channel activation can protect against ARDS triggered by...